Drug Trial Radar · NCT05775848
Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
112
Actual
Start
May 31, 2023
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- ML Bio Solutions, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of long-term administration of BBP-418 in patients with LGMD2I/R9. The study will include patients ages 12 to 60, consistent with the existing preclinical toxicology profile. This will encompass the significant majority of existing diagnosed patients based upon the established epidemiology of the disease.
Conditions
- Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
Interventions
BBP-418 (ribitol)Drug
The BBP-418 drug product is provided as Granules for Oral solution consisting of BBP-418 drug substance and silicon dioxide in a multilaminate sachet with a foil barrier. Silicon dioxide is generally regarded as safe and listed in the FDA IIAD. Silicon dioxide is a compendial excipient and is commonly used in pharmaceutical dosage forms. The BBP-418 Granules for Oral Solution are provided in sachets.The BBP-418 Granules for Oral Solution are reconstituted in water for oral administration.
PlaceboOther
A placebo matched for similar taste and appearance.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in North Star Assessment for Limb Girdle Muscular Dystrophy following 36 months of treatment to assess efficacy of BBP-418 or placeboTime frame: 36 months
- Frequency and severity of treatment-emergent adverse events following 36 months of treatment to assess safety of BBP-418 or placeboTime frame: 36 months
Locations
21 sites in 8 countries. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas
University of California Irvine
Irvine, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
University of Florida
Gainesville, Florida
University of Iowa
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
Kennedy Krieger Institute
Baltimore, Maryland
University of Minnesota, Twin Cities
Minneapolis, Minnesota
Washington University School of Medicine
St Louis, Missouri
Oregon Health & Science University (OHSU) - Neurology Clinic - South Waterfront
Portland, Oregon
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
Children's Hospital of the Kings Daughters
Norfolk, Virginia
Royal Brisbane and Women's Hospital,
Brisbane, Queensland, Australia
Rigshospitalet, Neuromuscular Clinic and Research Unit
Copenhagen, Denmark
Charité Universitätsmedizin Berlin and Max Delbrück Center
Berlin, Germany
IRCCS Ca' Granda Ospedale
Milan, Italy
Leiden University Medical Center
Leiden, Netherlands
Universitetssykehuset Nord-Norge, Department of Neurology
Tromsø, Norway
Great Ormond Street Hospital for Children
London, United Kingdom
International Centre for Life
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.